1. 174 Secukinumab demonstrates consistent safety over long-term exposure up to three years in patients with active ankylosing spondylitis: pooled analysis of three Phase III trials. (25th April 2018) Authors: Barkham, Nick; Deodhar, Atul; Baraliakos, Xenofon; Marzo-Ortega, Helena; Sieper, Joachim; Andersson, Mats; Porter, Brian; Fox, Todd Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 176 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies. (25th April 2018) Authors: Marzo-Ortega, Helena; Kvien, Tore K; Deodhar, Atul A; Gossec, Laure; Conaghan, Philip G; Strand, Vibeke; Østergaard, Mikkel; Williams, Nicole; Porter, Brian; Gandi, Kunal; Jugl, Steffen Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 260 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis. (12th April 2019) Authors: Marzo-Ortega, Helena; Deodhar, Atul; Miceli-Richard, Corinne; Baraliakos, Xenofon; Gladman, Dafna D; Martin, Ruvie; Safi, Jorge; Porter, Brian; Shete, Abhijit Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period. (12th April 2019) Authors: McInnes, Iain B; Deodhar, Atul; Gladman, Dafna D; Ren, Mengyuan; Spindeldreher, Sebastian; Pricop, Luminita; Porter, Brian; Safi, Jorge; Shete, Abhijit; Bruin, Gerard Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 264 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. (12th April 2019) Authors: Emery, Paul; Baraliakos, Xenofon; Braun, Jürgen; Deodhar, Atul; Poddubnyy, Denis; Delicha, Eumorphia-Maria; Talloczy, Zsolt; Porter, Brian Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Comprehensive nodal breast VMAT: solving the low‐dose wash dilemma using an iterative knowledge‐based radiotherapy planning solution. Issue 1 (12th August 2021) Authors: Stanton, Cameron; Bell, Linda J.; Le, Andrew; Griffiths, Brooke; Wu, Kenny; Adams, Jessica; Ambrose, Leigh; Andree‐Evarts, Denise; Porter, Brian; Bromley, Regina; van Gysen, Kirsten; Morgia, Marita; Lamoury, Gillian; Eade, Thomas; Booth, Jeremy T.; Carroll, Susan Journal: Journal of medical radiation sciences Issue: Volume 69:Issue 1(2022) Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). Issue 12 (December 2016) Authors: Deodhar, Atul A.; Dougados, Maxime; Baeten, Dominique L.; Cheng‐Chung Wei, James; Geusens, Piet; Readie, Aimee; Richards, Hanno B.; Martin, Ruvie; Porter, Brian Journal: Arthritis & rheumatology Issue: Volume 68:Issue 12(2016) Page Start: 2901 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52‐week pooled results from two phase 3 studies. (25th May 2017) Authors: Wei, James C.‐C.; Baeten, Dominique; Sieper, Joachim; Deodhar, Atul; Bhosekar, Vaishali; Martin, Ruvie; Porter, Brian Journal: International journal of rheumatic diseases Issue: Volume 20:Number 5(2017) Page Start: 589 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. EP38 Secukinumab provides sustained improvement of enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal Phase 3 studies. (20th April 2020) Authors: Barkham, Nick; Schett, Georg; Baraliakos, Xenofon; van den Bosch, Filip; Deodhar, Atul; Gensler, Lianne S; Ǿstergaard, Mikkel; Agawane, Shital; Gupta, Ayan Das; Mpofu, Shephard; Fox, Todd; Winseck, Adam; Shete, Abhijit; Porter, Brian Journal: Rheumatology Issue: Volume 59(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. FRI0380 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES. (June 2019) Authors: Schett, Georg; Baraliakos, Xenofon; Bosch, Filip van den; Deodhar, Atul; Gensler, Lianne S.; Ǿstergaard, Mikkel; Agawane, Shital; Gupta, Ayan Das; Mpofu, Shephard; Fox, Todd; Winseck, Adam; Shete, Abhijit; Porter, Brian Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 873 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗